Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
GSK Stock News and Mentions of GlaxoSmithKline plc Stocktwits
Updated: April 27, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where GlaxoSmithKline Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of GlaxoSmithKline plc (GSK).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the GlaxoSmithKline stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of GlaxoSmithKline plc (GSK)
April 26, 2024 (18:45) / "Benzinga" (by Vandana Singh)
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle - CureVac ( NASDAQ:CVAC )
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV CVAC have settled Acuitas' lawsuit over credit for inventions tied to COVID-19 vaccines. In November 2023, Acuitas Therapeutics filed a lawsuit in Virginia federal court against CureVac, accusing it of failing to credit ...
In Article Trend: Neutral
April 25, 2024 (17:51) / "Benzinga" (by Vandana Singh)
What's Going On With Pfizer Stock On Thursday? - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
GSK Plc GSK has reportedly taken legal action against Pfizer Inc PFE and BioNTech SE BNTX in a Delaware federal court, alleging patent infringement concerning mRNA technology used in the COVID-19 vaccines. The lawsuit contends that Pfizer and BioNTech's Comirnaty vaccines violate GSK's patents.
In Article Trend: Neutral
April 23, 2024 (17:16) / "Zacks Commentary" (by Zacks Equity Research)
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
In Article Trend: Neutral
April 18, 2024 (17:55) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
In Article Trend: Neutral
April 18, 2024 (16:06) / "Benzinga" (by Vandana Singh)
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future - 23andMe Holding ( NASDAQ:ME )
Anne Wojcicki, co-founder and chief executive of 23andMe Holding Co ME, is contemplating taking the genetics testing company private. This potential move comes after a tumultuous three years in public markets that witnessed a significant decline in the company's valuation, once at $6 billion.
In Article Trend: Neutral
April 17, 2024 (12:14) / "Zacks Commentary" (by Zacks Equity Research)
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
In Article Trend: Somewhat-Bullish
April 15, 2024 (18:12) / "Zacks Commentary" (by Zacks Equity Research)
Adaptimmune ( ADAP ) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company. s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
In Article Trend: Somewhat-Bullish
April 11, 2024 (11:48) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields - Patterson Cos ( NASDAQ:PDCO ) , GSK ( NYSE:GSK )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
April 4, 2024 (16:18) / "Benzinga" (by Vandana Singh)
CureVac, GS Partner Release Data On Influenza Vaccine Study - CureVac ( NASDAQ:CVAC ) , GSK ( NYSE:GSK )
CureVac N.V. CVAC released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc GSK.
In Article Trend: Neutral
April 4, 2024 (13:16) / "Benzinga" (by Vandana Singh)
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster - Sanofi ( NASDAQ:SNY )
Sanofi SA SASY has announced an agreement in principle to settle approximately 4,000 lawsuits in the United States linked to the discontinued heartburn drug Zantac. The company stated that the settlement encompasses many pending cases across various U.S. state courts, excluding Delaware.
In Article Trend: Neutral
March 27, 2024 (16:04) / "Benzinga" (by Globe Newswire)
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position - Algernon Pharmaceuticals ( OTC:AGNPF )
VANCOUVER, British Columbia, March 27, 2024 ( GLOBE NEWSWIRE ) -- Algernon Pharmaceuticals Inc. ( the "Company" or "Algernon" ) AGN AGW AGNPF, a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc. ( "Seyltx" ) , ...
In Article Trend: Neutral
March 27, 2024 (16:04) / "GlobeNewswire" (by Algernon Pharmaceuticals Inc.)
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
VANCOUVER, British Columbia, March 27, 2024 ( GLOBE NEWSWIRE ) -- Algernon Pharmaceuticals Inc. ( the "Company" or "Algernon" ) ( CSE: AGN ) ( FRANKFURT: AGW0 ) ( OTCQB: AGNPF ) , a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its ...
In Article Trend: Neutral
March 21, 2024 (16:29) / "Zacks Commentary" (by Zacks Equity Research)
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
In Article Trend: Neutral
March 21, 2024 (11:17) / "Benzinga" (by Vandana Singh)
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month - GSK ( NYSE:GSK )
On Wednesday, GSK Plc GSK announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease ( COPD ) medicines. The program will be implemented by January 1, 2025.
In Article Trend: Neutral
March 20, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:46) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) Follows Boehringer, to Cap Inhaler Cost in US
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
In Article Trend: Neutral
March 19, 2024 (15:08) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) to Decrease Stake in Haleon From 32% to 24%
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
In Article Trend: Neutral
March 18, 2024 (16:17) / "Benzinga" (by Vandana Singh)
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer - GSK ( NYSE:GSK )
Saturday, GSK plc GSK announced overall survival ( OS ) results from Part 1 and progression-free survival ( PFS ) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial of Jemperli ( dostarlimab ) for primary advanced or recurrent endometrial cancer, paving the way for a potential ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (15:02) / "Zacks Commentary" (by Zacks Equity Research)
Immuneering ( IMRX ) Plummets 71% in One Week: Here's Why
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
In Article Trend: Neutral
March 18, 2024 (10:55) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Gets FDA Panel Vote for Carvykti's Expanded Use
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:32) / "Zacks Commentary" (by Zacks Equity Research)
Allogene's ( ALLO ) Q4 Loss Narrower Than Expected, Sales Miss
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
In Article Trend: Neutral
March 15, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Breyanzi's Label Expansion
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In Article Trend: Neutral
March 15, 2024 (12:57) / "Zacks Commentary" (by Zacks Equity Research)
Geron ( GERN ) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
In Article Trend: Neutral
March 14, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Gets EU Nod for Expanded Use of Pneumococcal Jab
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:15) / "Zacks Commentary" (by Zacks Equity Research)
Allogene ( ALLO ) Inks Deal With Arbor Bio for CRISPR Technology
Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
In Article Trend: Neutral
March 13, 2024 (16:09) / "Zacks Commentary" (by Zacks Equity Research)
Regulus ( RGLS ) Up 71% on Topline Data from Kidney Disease Study
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
In Article Trend: Neutral
March 13, 2024 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer's ( PFE ) Adcetris Meets Survival Goal in Lymphoma Study
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
In Article Trend: Somewhat-Bullish
March 12, 2024 (17:52) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) Posts Positive Results on Opzelura From HS Study
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
In Article Trend: Neutral
March 12, 2024 (14:20) / "Benzinga" (by Globe Newswire)
Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics ( NASDAQ:AGRX ) , GSK ( NYSE:GSK )
New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.
In Article Trend: Somewhat-Bullish
March 11, 2024 (16:34) / "Zacks Commentary" (by Zacks Equity Research)
Amylyx's ( AMLX ) ALS Drug Fails Pivotal Study, Stock Down 82%
Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.
In Article Trend: Neutral
March 11, 2024 (14:38) / "Benzinga" (by Piero Cingari)
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' - AstraZeneca ( NASDAQ:AZN ) , ASML Holding ( NASDAQ:ASML )
Goldman Sachs has flagged an increasing concern over the U.S. stock market's heavy concentration and the dominant sway of its largest tech stocks, urging investors to broaden their geographical diversification.
In Article Trend: Neutral
March 11, 2024 (10:34) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Stock Down as FDA Delays Decision on Donanemab
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
In Article Trend: Neutral
March 7, 2024 (17:34) / "Zacks Commentary" (by Zacks Equity Research)
Emergent ( EBS ) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
In Article Trend: Neutral
March 7, 2024 (17:18) / "Benzinga" (by Vandana Singh)
Why Is GSK Stock Trading Higher On Thursday? - GSK ( NYSE:GSK )
GSK plc GSK released headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep ( belantamab mafodotin ) combination for relapsed or refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 6, 2024 (22:00) / "Benzinga" (by Vandana Singh)
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
ViiV Healthcare, majority owned by GSK Plc GSK, with Pfizer Inc PFE and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial.
In Article Trend: Neutral
March 6, 2024 (16:26) / "Zacks Commentary" (by Zacks Equity Research)
Alnylam ( ALNY ) , Roche's Blood Pressure Drug Meets Study Goal
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
In Article Trend: Somewhat-Bullish
March 5, 2024 (17:57) / "Benzinga" (by Vandana Singh)
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
The World Health Organization ( WHO ) released its latest HIV Drug Resistance ( HIVDR ) Report, shedding light on the growing areas of drug resistance and providing crucial recommendations for countries to navigate potential challenges.
In Article Trend: Neutral
March 4, 2024 (16:39) / "Benzinga" (by Vandana Singh)
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges - Gilead Sciences ( NASDAQ:GILD ) , GSK ( NYSE:GSK )
The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including HIV-preventing medication and cancer screenings, without additional costs to patients. This mandate is integral to the 2010 Affordable Care Act ( ACA ) ...
In Article Trend: Neutral
March 4, 2024 (01:44) / "Money Control"
Serum boosts supply of cervical cancer shots ahead of government's mass drive
Adar Poonawalla, the CEO of the world's biggest vaccine maker by the number of doses, told Reuters that he expects the vaccine to be a part of the government's programme by year-end.
In Article Trend: Neutral
February 29, 2024 (17:45) / "Benzinga" (by Vandana Singh)
Why Is Haleon Stock Trading Higher Today? - Haleon ( NYSE:HLN )
Haleon Plc's HLN fiscal year 2023 revenues increased 4.1% Y/Y to £11.3 billion, equivalent to around $14.03 billion, missing the consensus of $14.47 billion. Revenue grew 8.0% organically for FY 2023, with 7.0% price and 1.0% volume/mix, the company reported on Thursday.
In Article Trend: Somewhat-Bullish
February 29, 2024 (14:21) / "Benzinga" (by Vandana Singh)
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month - GSK ( NYSE:GSK )
Thursday, GSK Plc GSK agreed to confidentially settle another lawsuit in California that had alleged its heartburn drug Zantac ( ranitidine ) , now discontinued, caused cancer. The case, which was set to begin trial on April 2, will be dismissed.
In Article Trend: Neutral
February 28, 2024 (19:43) / "Benzinga" (by Stjepan Kalinic)
Granolas 11 Vs. Magnificent 7: Low Volatility, Higher Yields - AstraZeneca ( NASDAQ:AZN ) , ASML Holding ( NASDAQ:ASML )
While many of the world's investors remain focused on "The Magnificent Seven" - a group of tech stocks that significantly outperformed in 2023 - a small group of European stocks has quietly outperformed most of the world.
In Article Trend: Somewhat-Bullish
February 28, 2024 (12:00) / "GlobeNewswire" (by Inc.)
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website